Table 1.
Main clinical characteristic of T-ALL and T-LBL patients included in the study.
| T-ALL patients (N= 57) | T-LBL patients (n=22) | ||
|---|---|---|---|
| Gender (n, %) | Gender (n, %) | ||
| Male | 44 (77%) | Male | 18 (82%) |
| Female | 13 (23%) | Female | 4 (18%) |
| Age, years (n,%) | Age, years (n, %) | ||
| > 8.7 | 27 (47%) | > 10.1 | 11 (50%) |
| ≤ 8.7 | 30 (53%) | ≤ 10.1 | 11 (50%) |
| Immunophenotype (n, %) | Stage (n, %) | ||
| Early T (T-I and T-II) | 6 (12%) | III | 13* (60%) |
| Intermediate T (T-III or cortical) | 43 (75%) | IV | 9# (40%) |
| Mature T (T-IV) | 6 (10%) | BM involvement (n, %) | |
| NA | 2 (3%) | yes | 7 (32%) |
| Response to Prednisone (n, %) | no | 15 (68%) | |
| Good | 28 (50%) | CNS involvement (n, %) | |
| Poor | 20 (35%) | yes | 1 (5%) |
| NA | 9 (15%) | no | 21 (95%) |
| Follow-up (n, %) | Follow-up (n, %) | ||
| Complete remission | NA | Complete remission | 15 (68%) |
| Relapse | 4 (7%) | Relapse | 3 (13.5%) |
| Progression | 3 (13.5%) | ||
| Resistance | 1 (5%) | ||
BM, bone marrow; CNS, central nervous system; NA, not available.
*5/13 relapsed/resistant.
#2/9 relapsed/resistant.